Mucin as a therapeutic target in pseudomyxoma peritonei

Haroon A. Choudry, Mark E. O'Malley, Zong Sheng Guo, Herbert J. Zeh, David L. Bartlett

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. © 2012 Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)911-917
Number of pages7
JournalJournal of Surgical Oncology
Volume106
Issue number7
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Pseudomyxoma Peritonei
Mucins
Neoplasms
Goblet Cells
Cell Lineage
Therapeutics
Ascites
Cell Differentiation

Keywords

  • chemoperfusion
  • goblet cells
  • mucin
  • pseudomyxoma peritonei
  • targeted therapy
  • transcriptional regulation

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Choudry, H. A., O'Malley, M. E., Guo, Z. S., Zeh, H. J., & Bartlett, D. L. (2012). Mucin as a therapeutic target in pseudomyxoma peritonei. Journal of Surgical Oncology, 106(7), 911-917. https://doi.org/10.1002/jso.23146

Mucin as a therapeutic target in pseudomyxoma peritonei. / Choudry, Haroon A.; O'Malley, Mark E.; Guo, Zong Sheng; Zeh, Herbert J.; Bartlett, David L.

In: Journal of Surgical Oncology, Vol. 106, No. 7, 01.12.2012, p. 911-917.

Research output: Contribution to journalReview article

Choudry, HA, O'Malley, ME, Guo, ZS, Zeh, HJ & Bartlett, DL 2012, 'Mucin as a therapeutic target in pseudomyxoma peritonei', Journal of Surgical Oncology, vol. 106, no. 7, pp. 911-917. https://doi.org/10.1002/jso.23146
Choudry, Haroon A. ; O'Malley, Mark E. ; Guo, Zong Sheng ; Zeh, Herbert J. ; Bartlett, David L. / Mucin as a therapeutic target in pseudomyxoma peritonei. In: Journal of Surgical Oncology. 2012 ; Vol. 106, No. 7. pp. 911-917.
@article{0aa316ceee67415eb24768f866d1875f,
title = "Mucin as a therapeutic target in pseudomyxoma peritonei",
abstract = "Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. {\circledC} 2012 Wiley Periodicals, Inc.",
keywords = "chemoperfusion, goblet cells, mucin, pseudomyxoma peritonei, targeted therapy, transcriptional regulation",
author = "Choudry, {Haroon A.} and O'Malley, {Mark E.} and Guo, {Zong Sheng} and Zeh, {Herbert J.} and Bartlett, {David L.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/jso.23146",
language = "English (US)",
volume = "106",
pages = "911--917",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Mucin as a therapeutic target in pseudomyxoma peritonei

AU - Choudry, Haroon A.

AU - O'Malley, Mark E.

AU - Guo, Zong Sheng

AU - Zeh, Herbert J.

AU - Bartlett, David L.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. © 2012 Wiley Periodicals, Inc.

AB - Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. © 2012 Wiley Periodicals, Inc.

KW - chemoperfusion

KW - goblet cells

KW - mucin

KW - pseudomyxoma peritonei

KW - targeted therapy

KW - transcriptional regulation

UR - http://www.scopus.com/inward/record.url?scp=84868348442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868348442&partnerID=8YFLogxK

U2 - 10.1002/jso.23146

DO - 10.1002/jso.23146

M3 - Review article

C2 - 22585683

AN - SCOPUS:84868348442

VL - 106

SP - 911

EP - 917

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 7

ER -